IperionX's Titanium Ambitions Collide With Investor Impatience

Fund managers weigh a US government backed titanium ramp against a widening loss and a short seller battle that tested the thesis

30 Apr 2026 · 7 min read

After a brutal March, IperionX gave investors a reason to believe again in April 2026. Pengana Capital Group said the stock rose 22 per cent after the company delivered quarterly results, a detailed company presentation and its first public webcast in several years, coupled with management share purchases. The presentation outlined eight customer segments with 21 different prototypes under development for market entry across 2026, 2027 and 2028, alongside a titanium powder production ramp targeting an annualised run rate of 200 tonnes by the end of 2026, 1,400 tonnes by the end of 2027 and more than 10,000 tonnes by the end of 2030.

That rebound followed a genuinely rough patch. Ellerston Capital reported the stock plummeted 22 per cent in March 2026 after IperionX reported a first-half FY26 earnings loss of US$34.8 million, far worse than expected and more than double the US$16.2 million loss in the prior corresponding half. The manager said the collapse, which took the stock down 48 per cent for the month according to Pengana Capital Group, reflected growing investor impatience with the company's continued absence of commercial revenue despite its ambitious scaling plans.

The overall collapse this month reflects growing impatience with the company's continued absence of commercial revenue, despite its ambitious scaling plans.

— Ellerston Capital, Monthly Report, March 2026

A short-seller report that tested the thesis

The stock had already been through one major stress test in late 2025, when a short-seller report from Spruce Point Capital Management sent shares into a two-day trading halt after Ellerston Capital noted the stock had rallied 137 per cent over the prior year and briefly reached a high of $9.10. Pengana Capital Group, the company's largest holding at the time, said the report focused on what it considered trivial matters, such as photographs of disused offices, but also challenged the company's core titanium metal technology and its ability to secure cheap titanium scrap feedstock. The manager pushed back on both points, arguing IperionX is uniquely positioned to use small oxidised machine turnings that are abundant and cheap but currently unusable by the rest of the industry, and that its strategy of pressing low-cost angular powder into near-net-shape parts using its proprietary HSPT process, rather than competing in the spherical powder market, supports very high potential margins.

We believe the company is making strong operational progress, and the next 12 months should be transformative as production ramps at the Virginia facility.

— Pengana Capital Group, Monthly Report, October 2025

Pengana Capital Group followed up in November 2025, after the stock fell a further 23 per cent, noting broker Petra had visited the Virginia facility and released a detailed, positive report countering much of the short case, and said it viewed the market capitalisation at the time, around US$1.1 billion, as a bargain given the Titan mining project alone carried an approved net present value of US$700 million and is rich in heavy rare earths, which are in shorter supply than light rare earths.

The economics behind the capacity build-out

The scale of the opportunity, when the ramp works, was laid out by Pengana Capital Group in September 2025, when IperionX detailed capacity expansion plans targeting 1,400 tonnes of titanium production by 2027 and 10,000 tonnes by 2030, against US annual titanium consumption of around 100,000 tonnes. The manager estimated the 1,400-tonne milestone alone could generate between US$100 million and US$450 million of EBITDA depending on pricing, with the 10,000-tonne target potentially yielding around US$1 billion in EBITDA, albeit with prices likely to decline as volumes scale. Wilson Asset Management's earlier July 2025 update had already flagged the commercial building blocks behind that ambition, noting the commissioning of the company's Titanium Manufacturing Campus, a USD46 million private placement to accelerate US production, and a US$1.3 million task order under a broader USD99 million Department of Defense contract for titanium vehicle parts.

Continued US government support

That government backing has been a recurring theme. Ellerston Capital reported in January 2026 that the Department of War obligated the final US$4.6 million under IperionX's previously announced US$47.1 million award, alongside a smaller prototype purchase order from American Rheinmetall for 700 lightweight titanium components used in US Army ground combat systems, with potential for a significantly larger follow-on agreement. Pengana Capital Group noted the stock also benefited from inclusion in the REMX critical minerals ETF that same month, which drove substantial passive buying.

What managers are watching next

With 21 prototypes now in development across eight customer segments and production targets stretching out to 2030, the central question for managers is whether IperionX can convert its prototype pipeline and government-backed funding into the commercial revenue that has so far been missing, and whether the capacity ramp at Virginia meets the milestones management has now laid out in public detail for the first time in years.